Sigyn Therapeutics, Inc.
SIGY
$4.10
-$0.0099-0.24%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 66.20% | -8.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 34.12% | -4.32% | |||
| Operating Income | -34.12% | 4.32% | |||
| Income Before Tax | -38.79% | -13.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -38.79% | -13.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -38.79% | -13.76% | |||
| EBIT | -34.12% | 4.32% | |||
| EBITDA | -34.20% | 4.30% | |||
| EPS Basic | -35.45% | -13.03% | |||
| Normalized Basic EPS | -35.45% | -13.04% | |||
| EPS Diluted | -34.77% | -12.90% | |||
| Normalized Diluted EPS | -35.45% | -13.04% | |||
| Average Basic Shares Outstanding | 2.48% | 0.63% | |||
| Average Diluted Shares Outstanding | 2.48% | 0.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
